SCHEMBL3781462

SCHEMBL3781462

Cc1nc2cc(O)cc(Cl)c2c(C)c1Cc1ccc(Cl)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 1/20 0.42
RORC P51449 1/20 0.41
ENPP2 Q13822 1/20 0.41
MAPT P10636 4/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KMT2A Q03164 3/20 0.40
KDM4E B2RXH2 3/20 0.38
ENPP1 P22413 1/20 0.37
MEN1 O00255 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CDC7 O00311 1/20 0.36
DBF4 Q9UBU7 1/20 0.36
ALOX5 P09917 1/20 0.36
HSP90AB1 P08238 1/20 0.35
P2RX3 P56373 1/20 0.35
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3777248 0.83 RORC (0.41) PLA2G2ARORCENPP2MAPTLMNA
SCHEMBL3788414 0.82 RORC (0.41) PLA2G2ARORCENPP2MAPTLMNA
SCHEMBL3772903 0.75 PLA2G2A (0.40) PLA2G2ARORCENPP2MAPTLMNA
SCHEMBL3775557 0.75 KMT2A (0.40) RORCENPP2MAPTKMT2AKDM4E
SCHEMBL3777107 0.74 KDM4E (0.46) PLA2G2ARORCENPP2MAPTLMNA
SCHEMBL3780495 0.73 PTGDR2 (0.48) PLA2G2ARORCENPP2LMNASMN1; SMN2
SCHEMBL27826433 0.73 PLA2G2A (0.43) PLA2G2ARORCENPP2MAPTLMNA
SCHEMBL27826430 0.72 PLA2G2A (0.42) PLA2G2ARORCENPP2MAPTLMNA
SCHEMBL27722687 0.72 PLA2G2A (0.41) PLA2G2ARORCENPP2MAPTLMNA
SCHEMBL3777623 0.72 PLA2G2A (0.46) PLA2G2ALMNASMN1; SMN2L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 PLA2G2A 1779/4885RORC 30/4885ENPP2 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.